Topic
Durvalumab
AstraZeneca’s Imfinzi‑based combo slows liver cancer progression in late‑stage trial
London‑based pharma major AstraZeneca has reported that its liver‑cancer therapy combination, built around its immunotherapy Imfinzi (durvalumab), significantly slowed disease progression…
AstraZeneca Pharma India Receives CDSCO Approval for Durvalumab in Unresectable Hepatocellular Carcinoma
AstraZeneca Pharma India Ltd. (AZPIL), a global, science-led biopharmaceutical company, has announced that the Central Drugs Standard Control Organisation (CDSCO)…
AstraZeneca’s Durvalumab Gains CDSCO Approval, Reshaping LS-SCLC Treatment in India
The approval introduces a game-changing shift in the therapeutic landscape for LS-SCLC, a particularly aggressive subtype of lung cancer that…
AstraZeneca receives CDSCO approval for Tremelimumab combination in India
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC) AstraZeneca Pharma India…
AstraZeneca’s Durvalumab receives CDSCO approval in India
The molecule is used for the treatment of patients with locally advanced or metastatic Biliary Tract Cancer AstraZeneca India, a…